Novo Nordisk wins EU approval for Wegovy weight-loss pill

• Clinical trials showed patients taking the Wegovy pill lost approximately 17% of body weight on average, compared to about 3% for placebo recipients
• The approval covers oral semaglutide 25 mg for adults with BMI of at least 30, or at least 27 with one weight-related health condition, used alongside diet and exercise
• The Wegovy pill is currently available in the US, Britain, and UAE, with plans to launch in additional countries in the second half of 2026

Summary

Key Development: Novo Nordisk received European Commission approval on July 15 for its once-daily Wegovy pill (oral semaglutide 25 mg), making it the first oral GLP-1 weight-loss treatment authorized across the European Union.

Competitive Landscape: The approval gives Novo Nordisk a significant advantage over rival Eli Lilly, whose competing weight-loss pill Foundayo has not yet cleared EU regulatory pathways. This positions Novo as the early leader in the emerging oral weight-loss medication market.

Target Population & Efficacy: The treatment is approved for adults with a BMI of at least 30, or at least 27 with one weight-related health condition, to be used alongside diet and exercise. Clinical trial data demonstrated impressive results, with patients losing approximately 17% of body weight on average versus 3% for placebo recipients.

Safety Profile: Side effects aligned with the known safety profile of injectable semaglutide. Treatment discontinuation rates due to adverse effects were comparable between groups: 6.9% for the pill versus 5.9% for placebo.

Market Expansion: The oral Wegovy pill is currently available in the United States, Britain, and the UAE. Novo Nordisk plans to launch in additional countries during the second half of 2026.

Strategic Significance: CEO Mike Doustdar emphasized that the tablet format offers a simpler, more acceptable alternative to injections for some patients, potentially expanding market reach in the lucrative obesity treatment sector.

Investment Implications: This approval strengthens Novo Nordisk's dominant position in the rapidly growing weight-loss drug market and provides a competitive moat against rivals still navigating regulatory processes.